We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Testosterone (TRT)is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Testosterone (TRT) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2010–2024 with a typical study size of 5,246 participants.
Based on 9 studies · 2 meta-analyses · 5 RCTs · 61,629 total participants
Confidence
HighBy outcome
Testosterone (TRT) has an evidence score of 5.6/10 — moderate evidence based on 9 indexed studies, including 2 meta-analyses. The primary male androgen and an FDA-approved prescription drug for diagnosed male hypogonadism — and a Schedule III CONTROLLED SUBSTANCE. For men with genuinely low testosterone, randomized trials show real benefits: the Testosterone Trials (TTrials) improved sexual function, mood, anemia and bone density in older hypogonadal men, and the large TRAVERSE trial found TRT non-inferior to placebo for major cardiac events. But those benefits were modest and indication-specific, NOT a longevity or anti-aging result. It is prescription-only; non-medical, supraphysiologic, and 'anti-aging' use is illegal and carries serious harms — erythrocytosis, suppressed sperm production/fertility, cardiovascular and psychiatric risk. This is a harm-reduction reference, not a recommendation, and testosterone is NOT a dietary supplement. Representative study: PMID 37164187.
Tamoxifen (Nolvadex)
Mostly mechanism / observationalA selective estrogen receptor modulator (SERM) and one of the most successful cancer drugs ever made: in estrogen-receptor-positive breast cancer, five years of adjuvant tamoxifen cuts 15-year recurrence by roughly half and breast-cancer death by about a third (EBCTCG), and it prevents breast cancer in high-risk women (NSABP P-1). Among men it is used OFF-LABEL — it antagonizes estrogen in breast tissue to prevent or treat gynecomastia (well-supported by RCTs during antiandrogen therapy, and in idiopathic/pubertal cases), and it blocks estrogen feedback at the hypothalamus to raise LH/FSH and endogenous testosterone, which is why it appears in male-infertility regimens and bodybuilding post-cycle therapy (PCT). The honest limits are real and non-negotiable: tamoxifen raises the risk of endometrial cancer and venous thromboembolism (clots, pulmonary embolism, stroke) and can cause visual/ocular changes. It is NOT a longevity drug.
Notable regimens that report including Testosterone (TRT) — documented, not endorsed.
Last reviewed June 2026 · evidence from 9 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Testosterone — the primary androgen; testosterone-replacement therapy (TRT)
The primary male androgen and an FDA-approved prescription drug for diagnosed male hypogonadism — and a Schedule III CONTROLLED SUBSTANCE. For men with genuinely low testosterone, randomized trials show real benefits: the Testosterone Trials (TTrials) improved sexual function, mood, anemia and bone density in older hypogonadal men, and the large TRAVERSE trial found TRT non-inferior to placebo for major cardiac events. But those benefits were modest and indication-specific, NOT a longevity or anti-aging result. It is prescription-only; non-medical, supraphysiologic, and 'anti-aging' use is illegal and carries serious harms — erythrocytosis, suppressed sperm production/fertility, cardiovascular and psychiatric risk. This is a harm-reduction reference, not a recommendation, and testosterone is NOT a dietary supplement.
For diagnosed male hypogonadism the evidence is real and randomized: the Testosterone Trials improved sexual function, mood, anemia and bone density, RCT meta-analyses confirm gains in lean mass and modest strength, and the large TRAVERSE trial found TRT non-inferior to placebo for major adverse cardiac events. But those benefits are modest and indication-specific — NOT a longevity outcome — and testosterone is a Schedule III CONTROLLED SUBSTANCE (prescription-only) that even at therapeutic doses causes erythrocytosis and suppresses sperm production, with the earlier TOM trial and an observational MI signal as genuine cardiovascular counter-evidence, and serious cardiomyopathy/dyslipidemia/dependence risk in supraphysiologic non-medical use. Effective where indicated; legally controlled and genuinely harmful when misused.
Testosterone is the primary androgen — the steroid hormone, made chiefly by the testicular Leydig cells under pituitary LH control, that drives male sexual development, libido, erythropoiesis, muscle and bone mass, and mood.
Testosterone-replacement therapy (TRT) is the medical replacement of that hormone in men with diagnosed hypogonadism: biochemically low testosterone (typically confirmed on repeat morning measurements) plus consistent symptoms. In that population the evidence is genuinely strong and randomized.
The coordinated Testosterone Trials (TTrials) in symptomatic men 65 and older with unequivocally low testosterone showed that one year of gel raised testosterone to mid-normal young-male levels and improved sexual activity and desire, modestly improved mood and depressive symptoms, corrected anemia (both unexplained and iron-deficiency-pattern), and increased volumetric bone mineral density and estimated bone strength — but produced no benefit for cognition and only small gains in walking distance.
The large, cardiovascular-safety-powered TRAVERSE trial (Lincoff 2023, NEJM) then randomized middle-aged and older hypogonadal men with high cardiovascular risk and found transdermal testosterone non-inferior to placebo for major adverse cardiac events (cardiovascular death, nonfatal MI, nonfatal stroke) — reassuring on the central cardiovascular-safety question that had dogged the field, though it flagged more atrial fibrillation, acute kidney injury, and pulmonary embolism.
Meta-analysis of randomized trials confirms TRT reliably improves body composition — more lean mass, less fat mass — and modestly improves muscle strength and bone density. That is the honest, real, indication-bounded case for TRT.
The other side is what keeps this a gated, harm-reduction entry rather than a recommendation.
First, testosterone is a Schedule III CONTROLLED SUBSTANCE in the United States and a prescription-only medicine almost everywhere: obtaining or using it without a prescription is illegal, and the grey-market/non-medical supply is unregulated.
Second, the proven benefits are narrow and were never longevity outcomes — the TTrials were modest, time-limited (one year), and explicitly not a healthspan or lifespan trial, so framing TRT as 'anti-aging' overstates the evidence. Third, the harms are real and dose-dependent.
Even at therapeutic doses, testosterone commonly causes erythrocytosis/polycythemia (a rise in hematocrit that raises clot and stroke risk) and suppresses the hypothalamic-pituitary-testicular axis, shrinking the testes and dropping endogenous sperm production — testosterone is, in fact, the backbone of experimental male hormonal contraception precisely because it reliably suppresses spermatogenesis, so men wanting fertility should not be on it without a plan (hCG, enclomiphene, or sperm banking).
The earlier TOM trial (Basaria 2010, NEJM) in frail older men with mobility limitations was stopped early after more cardiovascular adverse events in the testosterone arm, and a large observational cohort (Finkle 2014) found an elevated rate of non-fatal myocardial infarction in the 90 days after a first testosterone prescription, especially in older men — the counter-evidence that TRAVERSE later tempered but did not erase.
Prostate considerations (TRT does not appear to cause prostate cancer but can raise PSA and is avoided in active prostate cancer) require monitoring.
And supraphysiologic, non-medical anabolic-steroid use — far above replacement doses — is a different and more dangerous activity, associated with cardiomyopathy and impaired cardiac function, adverse lipid changes (suppressed HDL), dependence, and mood/psychiatric effects.
The score reflects this split: real, randomized benefit for diagnosed hypogonadism (sexual function, mood, anemia, bone, body composition, and reassuring TRAVERSE cardiovascular safety) against a controlled-substance legal status, an unproven longevity claim, and documented hematologic, fertility, cardiovascular, and psychiatric harms — especially with non-medical or supraphysiologic use.
Testosterone is a prescription drug and a controlled substance, not a dietary supplement, and not a longevity agent.
Testosterone binds the intracellular androgen receptor, which translocates to the nucleus and drives androgen-responsive gene transcription — the basis for its effects on muscle and bone anabolism, libido, mood, and erythropoiesis.
Testosterone is converted by aromatase to estradiol (important for bone, mood, and libido) and by 5α-reductase to the more potent androgen dihydrotestosterone (DHT). Many testosterone effects are actually mediated by these metabolites, and the estradiol it produces is part of why it supports bone.
Exogenous testosterone signals the hypothalamus and pituitary that levels are sufficient, suppressing GnRH, LH and FSH — which shuts down endogenous testosterone and sperm production (testicular atrophy, infertility). It also stimulates erythropoiesis, raising hematocrit; the same axis suppression and red-cell rise are the core therapeutic-dose harms.
How Testosterone (TRT) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Prescription-only and clinician-directed — this is a controlled substance, NOT a self-administered supplement, and we do not provide a non-medical dosing protocol. For context only: TRT for diagnosed hypogonadism is titrated to a mid-normal testosterone level. Intramuscular testosterone esters (cypionate/enanthate) are commonly dosed around 50–100 mg weekly (or ~100–200 mg every 2 weeks); long-acting testosterone undecanoate is dosed less frequently. Transdermal gels (~50–100 mg/day applied) and subcutaneous injection are alternative routes. Supraphysiologic anabolic-steroid doses are far higher, illegal, and dangerous — not a regimen this library endorses.
Can be taken without food
| Form | Type |
|---|---|
| 💊Clinician-prescribed testosterone (intramuscular ester or transdermal gel) for diagnosed hypogonadism — controlled substance, prescription-only | Recommended |
| 💊Enclomiphene or clomiphene (raise endogenous testosterone while sparing fertility — for secondary hypogonadism) | Alternative |
| 💊hCG (maintains intratesticular testosterone and fertility, often added to TRT) | Alternative |
| 💊Treating the underlying cause of low testosterone (weight loss, sleep, opioids, etc.) before lifelong replacement | Alternative |
Form and route are a medical decision. For men who want to preserve fertility, exogenous testosterone is generally the wrong choice because it suppresses spermatogenesis — fertility-sparing options (enclomiphene, hCG) or sperm banking should be discussed first.
Compare Testosterone (TRT) vs HCG (Human Chorionic Gonadotropin) →Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: Clinician-directed and titrated to a target serum testosterone with hematocrit and PSA monitoring — not a fixed supplement schedule. Injection frequency depends on the ester; gels are applied daily.
Dose-response data unavailable. The current published research for Testosterone (TRT) does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
In the Testosterone Trials, one year of TRT in older hypogonadal men improved sexual activity, desire, and erectile function — the most consistent symptomatic benefit in diagnosed deficiency.
RCT meta-analyses show TRT increases lean mass, reduces fat mass, modestly increases muscle strength, and raises bone mineral density and estimated bone strength in hypogonadal men.
The TTrials corrected anemia (including unexplained anemia) and produced small improvements in mood and depressive symptoms — but no cognitive benefit.
Even at therapeutic doses TRT raises hematocrit (polycythemia, clot/stroke risk) and suppresses the HPTA — shrinking the testes and reducing sperm production. It is used experimentally as male contraception precisely because it suppresses fertility.
TRAVERSE found TRT non-inferior to placebo for major cardiac events but flagged more atrial fibrillation, acute kidney injury and pulmonary embolism; the earlier TOM trial stopped early for cardiovascular events. Supraphysiologic non-medical use adds cardiomyopathy, low HDL, dependence and mood disturbance.
The TTrials benefits were modest and limited to one year in diagnosed deficiency. There is no trial showing TRT extends healthspan or lifespan, so 'anti-aging' use is not evidence-based.
This is the indication the RCT evidence supports. Confirm with repeat morning testosterone, treat under a clinician, and monitor hematocrit and PSA. Benefits are real but modest — not a performance or longevity intervention.
Exogenous testosterone suppresses sperm production — generally the wrong choice. Discuss fertility-sparing options (enclomiphene, hCG) or sperm banking first.
TRAVERSE was reassuring on major cardiac events but flagged atrial fibrillation, AKI and pulmonary embolism, and the TOM trial stopped early for cardiovascular events in frail men. Assess cardiovascular risk carefully before and during therapy.
Avoid — it is a Schedule III controlled substance, illegal without a prescription, the 'anti-aging' benefit is unproven, and supraphysiologic use carries cardiomyopathy, lipid, fertility, hematologic and psychiatric harm.
Contraindicated in active prostate cancer; TRT can raise PSA. PSA and prostate exam should be checked before and during therapy.
Testosterone can potentiate anticoagulant effect and raise bleeding risk; INR and dosing need monitoring. The erythrocytosis it causes also independently affects clot risk.
Stacking androgenic agents (common in non-medical use) compounds erythrocytosis, lipid and HPTA effects; aromatase inhibitors are sometimes added to manage estradiol but can over-suppress it and harm bone and lipids. Unvalidated and risky outside clinical care.
Tip: A dose-dependent rise in red cells that raises clot/stroke risk; requires periodic hematocrit checks and dose reduction or phlebotomy. Higher with injectable than transdermal forms.
Tip: Exogenous testosterone shuts down the HPTA and spermatogenesis. Men who may want children should consider hCG, enclomiphene, or sperm banking before starting; recovery after stopping is variable and can take months.
Tip: Flagged as more frequent on testosterone than placebo in TRAVERSE; report palpitations, leg swelling, chest pain or breathlessness. Cardiovascular risk should be assessed before and during therapy.
Tip: Non-medical anabolic-steroid doses are associated with impaired cardiac function/cardiomyopathy and suppressed HDL cholesterol. There is no safe self-directed high-dose regimen; this library does not provide one.
The commonly studied dose of Testosterone (TRT) is Prescription-only and clinician-directed — this is a controlled substance, NOT a self-administered supplement, and we do not provide a non-medical dosing protocol. For context only: TRT for diagnosed hypogonadism is titrated to a mid-normal testosterone level. Intramuscular testosterone esters (cypionate/enanthate) are commonly dosed around 50–100 mg weekly (or ~100–200 mg every 2 weeks); long-acting testosterone undecanoate is dosed less frequently. Transdermal gels (~50–100 mg/day applied) and subcutaneous injection are alternative routes. Supraphysiologic anabolic-steroid doses are far higher, illegal, and dangerous — not a regimen this library endorses.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Testosterone (TRT) — consistent daily use matters more than the time of day. There is no validated supplement timing — TRT is a prescription drug titrated by a clinician to a target serum testosterone (and monitored hematocrit/PSA), not a fixed self-dosing schedule.
Testosterone (TRT) should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are erythrocytosis / polycythemia (raised hematocrit), suppressed sperm production / infertility & testicular atrophy, atrial fibrillation, acute kidney injury, pulmonary embolism. Use caution if any of these apply to you: Use without a prescription / without medical supervision — testosterone is a Schedule III controlled substance and prescription-only; Active prostate cancer or active breast cancer in men; Untreated severe erythrocytosis / hematocrit above the safe threshold.
Exemestane
Mostly mechanism / observationalA steroidal, irreversible ('suicide') aromatase inhibitor (Aromasin) approved for hormone-receptor-positive breast cancer, where its evidence is strong (the IES switch trial, MAP.3 prevention, and head-to-head with anastrozole in MA.27). It is the steroidal counterpart to anastrozole and letrozole, and because its metabolite is mildly androgenic it is sometimes claimed to spare bone — but the trials show it still lowers bone-mineral density and raises fracture risk. Used off-label in men to lower estradiol and raise testosterone, a small crossover RCT confirms it does shift the hormones, but estrogen is required for the male skeleton and lipids. A prescription drug, not a supplement, and NOT a longevity drug.
Testosterone can improve insulin sensitivity and lower glucose, which may require adjustment of diabetes medication to avoid hypoglycemia.
Concurrent corticosteroids can increase fluid retention/edema, especially in patients with cardiac or renal disease.
Tip: Modest mood effects can occur at therapeutic doses; supraphysiologic use is linked to irritability/aggression, mood disorders, and androgen dependence. Monitor mood and avoid non-medical escalation.
Tip: Androgenic and aromatization-related effects; usually manageable with dose adjustment under a clinician.